SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Furthermore, weight loss and increased fatty acid oxidation during the administration of SGLT2 inhibitors could contribute to the reduction of hepatic fat accumulation in patients with T2DM and NAFLD [113].